Discover more from Courageous Discourse™ with Dr. Peter McCullough & John Leake
Ambulatory Ritonavir-Boosted Nirmatrelvir and Molnupiravir Associated with Reduced Hospitalization and Death
More than Half of Hospitalizations and Deaths were Vaccine Boosted Cleveland Clinic Patients
By Peter A. McCullough, MD, MPH
Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and in other countries as part of the McCullough Protocol to treat nonhospitalized patients who have mild-to-moderate COVID-19 and who are at high risk for progression to severe disease. Lin et al from the Cleveland Clinic reported on these two oral antiviral drugs with respect to hospitalization and death resulting from infection with new SARS-CoV-2 Omicron subvariants, particularly BQ.1.1 and XBB.1.5.
Because both drugs are a proxy for early multidrug intervention and a better standard of care than nothing, they were associated with substantial reductions in hospitalization and death as ivermectin and hydroxychloroquine have been demonstrated in similar prior non-randomized studies.
It was interesting to note that more than half of the hospitalizations and deaths occurred in fully vaccinated and boosted Cleveland Clinic patients.
The bottom line is that early multidrug therapy remains the community standard of care for high-risk COVID-19 and only those who receive no treatment are at risk for hospitalization and deaths. Vaccination has no impact on these serious outcomes.
Subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth at a time when you need it the most.
Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
Lin DY, Abi Fadel F, Huang S, Milinovich AT, Sacha GL, Bartley P, Duggal A, Wang X. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections. JAMA Netw Open. 2023 Sep 5;6(9):e2335077. doi: 10.1001/jamanetworkopen.2023.35077. PMID: 37733342; PMCID: PMC10514733.